The New Risk Management Problem in Drug Pricing
Executive Summary
Prices in Europe may be to a large extent under government control, but as the case of the UK's Napp Pharmaceuticals illustrates, companies still have enough flexibility to get themselves into trouble.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?